1Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics [J]. Arch Intern Med,2003, 163(1): 76-80.
2Gershengorn HB, Darby G, Blower SM. Predicting the emergence of drug-resistant HSV-2: new predictions[J]. BMC Infect Dis,2003, 3(1): 1.
3Pechere M, Wunderli W, Trellu-Toutous L, et al. Treatment of acyclovir-resistant herpetic ulceration with topical foscarnet and antiviral sensitivity analysis[J]. Dermatology, 1998, 197(3): 278-280.
4Chilukuri S, Rosen T. Management of acyclovir-resistant herpes simplex virus[J]. Dermatol Clin, 2003, 21(2): 311-320.
5Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir[J]. J Infect Dis, 2002, 186(Suppl 1): S40-46.
6Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group[J]. Genitourin Med, 1997, 73(2):110-116.
7Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial.Collaborative Famciclovir Genital Herpes Research Group[J].Arch Intern Med, 1997, 157(3): 343-349.
8Kroon S, Petersen CS, Andersen LP, et al. Long-term suppression of severe recurrent genital herpes simplex infections with oral acyclovir: a dose-titration study[J]. Genitourin Med, 1990,66(2): 101-104.
9Kinghorn Gl, Fiddian AP. Prevention of lesion development in recurrent genital herpes with oral valaciclovir [J]. J Eur Acad Dermatol Venereol, 1995, 5(Suppl 1): S162.
10Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment[J]. Clin Infect Dis, 2002, 34(7):958-962.
